Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia

Shinichiro Okamoto, Yoshitaka Miyakawa, Jonathan Smith, Ian Hodgson, Brihad Abhyankar, Steven Troy, Yuzuru Kanakura

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although anagrelide is widely used for the treatment of essential thrombocythemia (ET) in the USA and Europe, it is not licensed in Japan. Existing literature has reported differences in polymorphism and activity of CYP1A2 in Japanese and non-Japanese ethnic groups, which may alter anagrelide metabolism. We intended to identify the optimum dosage of anagrelide in treatmentnai ̈ve Japanese patients with ET and assess its long-term safety and efficacy. Twelve patients with ET and a platelet count of ≤80 × 104/μL were enrolled. Anagrelide was administered at an initial dose of 0.5 mg/day (weeks 1-4), then increased to 1.0 mg/day (weeks 5-8). During the following maintenance (weeks 9-52) and continuation periods (weeks 53-104), the dose was adjusted according to patient safety data and to maintain target platelet counts (<60 × 104/lL). Increasing the dose led to a decrease in mean platelet count, and target platelet counts were maintained in 11 patients. Adverse events were mild or moderate, and none led to discontinuation. This cohort of Japanese patients exhibited higher pharmacokinetic exposures of anagrelide and its active metabolite than those previously documented in non-Japanese patients. These differences were modest, suggesting specific dosing regimens for Japanese patients are not required.

Original languageEnglish
Pages (from-to)360-368
Number of pages9
JournalInternational Journal of Hematology
Volume97
Issue number3
DOIs
Publication statusPublished - 2013 Mar

Fingerprint

Essential Thrombocythemia
Pharmacokinetics
Platelet Count
Safety
Therapeutics
Cytochrome P-450 CYP1A2
Patient Safety
Ethnic Groups
anagrelide
Japan
Maintenance

Keywords

  • Anagrelide
  • Elevated platelet count
  • Essential thrombocythemia
  • Japanese patients
  • Pharmacokinetic profiles

ASJC Scopus subject areas

  • Hematology

Cite this

Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia. / Okamoto, Shinichiro; Miyakawa, Yoshitaka; Smith, Jonathan; Hodgson, Ian; Abhyankar, Brihad; Troy, Steven; Kanakura, Yuzuru.

In: International Journal of Hematology, Vol. 97, No. 3, 03.2013, p. 360-368.

Research output: Contribution to journalArticle

@article{978a5352db574046ae524c8c389b503d,
title = "Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-na{\"i}ve Japanese patients with essential thrombocythemia",
abstract = "Although anagrelide is widely used for the treatment of essential thrombocythemia (ET) in the USA and Europe, it is not licensed in Japan. Existing literature has reported differences in polymorphism and activity of CYP1A2 in Japanese and non-Japanese ethnic groups, which may alter anagrelide metabolism. We intended to identify the optimum dosage of anagrelide in treatmentnai ̈ve Japanese patients with ET and assess its long-term safety and efficacy. Twelve patients with ET and a platelet count of ≤80 × 104/μL were enrolled. Anagrelide was administered at an initial dose of 0.5 mg/day (weeks 1-4), then increased to 1.0 mg/day (weeks 5-8). During the following maintenance (weeks 9-52) and continuation periods (weeks 53-104), the dose was adjusted according to patient safety data and to maintain target platelet counts (<60 × 104/lL). Increasing the dose led to a decrease in mean platelet count, and target platelet counts were maintained in 11 patients. Adverse events were mild or moderate, and none led to discontinuation. This cohort of Japanese patients exhibited higher pharmacokinetic exposures of anagrelide and its active metabolite than those previously documented in non-Japanese patients. These differences were modest, suggesting specific dosing regimens for Japanese patients are not required.",
keywords = "Anagrelide, Elevated platelet count, Essential thrombocythemia, Japanese patients, Pharmacokinetic profiles",
author = "Shinichiro Okamoto and Yoshitaka Miyakawa and Jonathan Smith and Ian Hodgson and Brihad Abhyankar and Steven Troy and Yuzuru Kanakura",
year = "2013",
month = "3",
doi = "10.1007/s12185-013-1265-4",
language = "English",
volume = "97",
pages = "360--368",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia

AU - Okamoto, Shinichiro

AU - Miyakawa, Yoshitaka

AU - Smith, Jonathan

AU - Hodgson, Ian

AU - Abhyankar, Brihad

AU - Troy, Steven

AU - Kanakura, Yuzuru

PY - 2013/3

Y1 - 2013/3

N2 - Although anagrelide is widely used for the treatment of essential thrombocythemia (ET) in the USA and Europe, it is not licensed in Japan. Existing literature has reported differences in polymorphism and activity of CYP1A2 in Japanese and non-Japanese ethnic groups, which may alter anagrelide metabolism. We intended to identify the optimum dosage of anagrelide in treatmentnai ̈ve Japanese patients with ET and assess its long-term safety and efficacy. Twelve patients with ET and a platelet count of ≤80 × 104/μL were enrolled. Anagrelide was administered at an initial dose of 0.5 mg/day (weeks 1-4), then increased to 1.0 mg/day (weeks 5-8). During the following maintenance (weeks 9-52) and continuation periods (weeks 53-104), the dose was adjusted according to patient safety data and to maintain target platelet counts (<60 × 104/lL). Increasing the dose led to a decrease in mean platelet count, and target platelet counts were maintained in 11 patients. Adverse events were mild or moderate, and none led to discontinuation. This cohort of Japanese patients exhibited higher pharmacokinetic exposures of anagrelide and its active metabolite than those previously documented in non-Japanese patients. These differences were modest, suggesting specific dosing regimens for Japanese patients are not required.

AB - Although anagrelide is widely used for the treatment of essential thrombocythemia (ET) in the USA and Europe, it is not licensed in Japan. Existing literature has reported differences in polymorphism and activity of CYP1A2 in Japanese and non-Japanese ethnic groups, which may alter anagrelide metabolism. We intended to identify the optimum dosage of anagrelide in treatmentnai ̈ve Japanese patients with ET and assess its long-term safety and efficacy. Twelve patients with ET and a platelet count of ≤80 × 104/μL were enrolled. Anagrelide was administered at an initial dose of 0.5 mg/day (weeks 1-4), then increased to 1.0 mg/day (weeks 5-8). During the following maintenance (weeks 9-52) and continuation periods (weeks 53-104), the dose was adjusted according to patient safety data and to maintain target platelet counts (<60 × 104/lL). Increasing the dose led to a decrease in mean platelet count, and target platelet counts were maintained in 11 patients. Adverse events were mild or moderate, and none led to discontinuation. This cohort of Japanese patients exhibited higher pharmacokinetic exposures of anagrelide and its active metabolite than those previously documented in non-Japanese patients. These differences were modest, suggesting specific dosing regimens for Japanese patients are not required.

KW - Anagrelide

KW - Elevated platelet count

KW - Essential thrombocythemia

KW - Japanese patients

KW - Pharmacokinetic profiles

UR - http://www.scopus.com/inward/record.url?scp=84887573442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887573442&partnerID=8YFLogxK

U2 - 10.1007/s12185-013-1265-4

DO - 10.1007/s12185-013-1265-4

M3 - Article

C2 - 23378182

AN - SCOPUS:84887573442

VL - 97

SP - 360

EP - 368

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -